Containment Licensing Production 
Druggist
DECEMBER 17, 2020
Without a doubt, codeine-containing products are one of the most commonly sold medicines in the UK. Most codeine products are combination products of codeine and another drug. Restrictions on the supply of codeine-containing products. Codeine over the counter: UK list of products. Codeine and aspirin.
Druggist
NOVEMBER 10, 2020
Today I will list Calpol alternative products, including other brands and forms of liquid paracetamol and alternative drugs. Although the intention is to find Calpol alternative products for toddlers and children, I included a few products, which have a minimum age restriction of 12 years and above. Calpol alternative products.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Druggist
OCTOBER 21, 2020
The main products used for toenail fungus treatment are available in most pharmacies, supermarkets and perhaps with the best range of products found online. Topical products, which are applied directly to the infected area, are the main products used as toenail fungus treatment.
Camargo
NOVEMBER 11, 2020
Unpacking the (Black) Box: Antares Licenses Urology Product with Boxed Warning. When the FDA requires a product’s labeling to include a boxed warning (also called a “black box warning” because the text is surrounded by black border), the potential market value of the drug often drops severely. In October, the U.S.
Pharmaceutical Technology
MAY 25, 2023
The response was more powerful than that generated by MenACWY-D – a licensed quadrivalent meningococcal vaccine marketed by GSK. NmCV-5 should be a cheaper option compared to existing quadrivalent vaccines, owing to more cost-effective production methods. percentage points (96% CI, −0.3 for serogroup W to 20.5 for serogroup A.
Pharmaceutical Technology
JUNE 21, 2023
In the past year, Hemgenix has been granted approval by the US Food and Drug Administration (FDA) and has received conditional marketing authorisation from the European Commission (EC) and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). This followed positive results from CSL’s Phase III HOPE-B trial (NCT03569891).
Pharmaceutical Technology
OCTOBER 19, 2022
According to the deal, the worldwide rights for developing and marketing intratumoral combination treatment containing Eucure’s YH002 and two additional active ingredients of the Syncrovax therapy will be acquired by Syncromune.
Expert insights. Personalized for you.
98 
Let's personalize your content